Skip to main
ARVN
ARVN logo

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 30%
Buy 39%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

Arvinas Inc. demonstrates a promising outlook based on recent clinical trial data, particularly from the VERITAC-2 study, which revealed a statistically significant improvement in median progression-free survival (mPFS) for patients with ESR1 mutations, positioning the company favorably against competitors. The data also indicate that vepdegestrant (vepdeg) shows compelling differentiation and competitiveness, potentially exceeding a 4-month mPFS in the ESR1 mutant population, which could enhance its market position in monotherapy scenarios. Furthermore, the combination treatment with vepdeg has been deemed safe, with no dose-limiting toxicities or severe adverse events, bolstering confidence in its therapeutic potential.

Bears say

The financial outlook for Arvinas Inc appears negative due to several fundamental concerns regarding the efficacy and competitive positioning of its product candidates, particularly bavdegalutamide and vepdegestrant. There is apprehension over the restricted label likely resulting from insufficient benefit in the intent-to-treat population, which could hinder commercialization and push back clinical evidence timelines. Additionally, uncertainties surrounding pipeline momentum and the potential for new competitors to seize market share in earlier treatment lines further cloud the company’s revenue projections and overall growth potential.

Arvinas Inc (ARVN) has been analyzed by 23 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 39% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 23 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Sep 22, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.